Merck & Co Inc (MRK)

MRK on New York Consolidated

58.79USD
4 Aug 2015
Change (% chg)

$-0.26 (-0.44%)
Prev Close
$59.05
Open
$59.44
Day's High
$59.47
Day's Low
$58.76
Volume
1,373,859
Avg. Vol
9,342,901
52-wk High
$63.62
52-wk Low
$52.49

MRK

Chart for MRK

About

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine... (more)

Overall

Beta: 0.47
Market Cap(Mil.): $166,829.30
Shares Outstanding(Mil.): 2,825.22
Dividend: 0.45
Yield (%): 3.05

Financials

  MRK Industry Sector
P/E (TTM): 17.28 36.80 40.04
EPS (TTM): 3.42 -- --
ROI: -- 16.38 15.66
ROE: -- 17.14 16.66
Search Stocks

Merck raises forecast on strong sales of diabetes, cancer drugs

- Merck & Co Inc reported a better-than-expected quarterly profit and boosted its full-year earnings forecast as demand for its diabetes and cancer drugs increased.

28 Jul 2015

UPDATE 1-Merck raises forecast on strong sales of diabetes, cancer drugs

July 28 - Merck & Co Inc reported a better-than-expected quarterly profit and boosted its full-year earnings forecast as demand for its diabetes and cancer drugs increased.

28 Jul 2015

Strong dollar weighs on Merck revenue

July 28 - Merck & Co Inc reported a nearly 11 percent drop in quarterly revenue as a strong dollar and the sale of its consumer care business overshadowed strong demand for its diabetes drugs.

28 Jul 2015

Belgium's Ablynx triples cooperation deal with Merck & Co

BRUSSELS, July 22 - Belgian biotech group Ablynx on Wednesday said it had tripled its research deal with U.S. drugmaker Merck & Co leading to potential milestone payments of about 4 billion euros ($4.38 billion).

22 Jul 2015

BRIEF-Ablynx expands its immuno-oncology collaboration with Merck & Co

* Significantly expands its immuno-oncology collaboration with Merck & Co Inc

22 Jul 2015

UPDATE 1-Merck aims to be leader in OLED materials by 2018

* Merck is market leader in liquid crystals (Adds details on competitors, investment)

19 Jun 2015

Merck aims to be leader in OLED materials by 2018

DARMSTADT, Germany, June 19 - Germany's Merck aims to be a leading maker of OLED (organic light-emitting diode) materials by 2018, its head of chemicals said on Friday.

19 Jun 2015

Merck to pay $5.9 million for misleading marketing of pink eye drug: U.S

NEW YORK - Merck & Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday.

17 Jun 2015

Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.

NEW YORK - Merck & Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday.

17 Jun 2015

UPDATE 1-Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.

NEW YORK, June 17 - Merck & Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday.

17 Jun 2015

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$49.00
Provider : ValuEngine, Inc.
$25.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks